This Viewpoint reviews early evidence of improved outcomes among patients with cancer and higher BMIs treated with tumor checkpoint inhibitors, and the scientific challenges of distinguishing the mechanism of favorable vs adverse effects of obesity on cancer epidemiology and responses to treatment.
No takes yet. Share an insight, caveat, or question.
Murphy et al. (2019) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: